Adherence to highly active antiretroviral therapy in a tertiary care hospital in West Bengal, India

Singapore Medical Journal

Volumn 55, Issue 2, 2014, Pages 92-98

  Saha, Rajib ^a   Saha, Indranil ^b   Sarkar, Aditya Prasad ^a   Das, Dilip Kumar ^c   Misra, Raghunath ^a   Bhattacharya, Krishnadas ^a   Roy, Rabindra Nath ^a   Bhattacharya, Abantika ^a  

^a BURDWAN MEDICAL COLLEGE AND HOSPITAL   (India)

^b IQ City Medical College and IQ City Narayana Hrudayalaya Hospital   (India)

^c NORTH BENGAL MEDICAL COLLEGE   (India)

Author keywords

Adherence to HAART; ART centre; Nonadherence to HAART; PLWHA

Indexed keywords

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; CROSS-SECTIONAL STUDY; DRUG RESISTANCE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; INDIA; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PROCEDURES; QUALITY OF LIFE; QUESTIONNAIRE; RISK; RISK FACTOR; TERTIARY CARE CENTER; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE; FEMALE; HIV INFECTIONS; HUMANS; INDIA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 84894058901     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: 10.11622/smedj.2014021     Document Type: Article

References (41)

1. UNAIDS. UNAIDS report on the global AIDS epidemic 2010 [online]. Available at: http://www.unaids.org/globalreport/global_report.htm. Accessed April 24, 2013.
2. Government of India. HIV Sentinel Surveillance and HIV estimation in India 2007, A Technical Brief. New Delhi: NACO, Ministry Of Health and Family Welfare, 2008.
3. West Bengal State AIDS Prevention and Control Society. Annual report 2009-10 [online]. Available at: www.wbhealth.gov.in/wbsapcs/report/ Annual%20Report09-10Final.pdf. Last accessed April 10, 2012.
4. Mannheimer SB, Matts J, Telzak E, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care 2005; 17:10-22.
5. Tadios Y, Davey G. Antiretroviral treatment adherence and its correlates among people living with HIV/AIDS on highly active antiretroviral therapy in Addis Ababa, Ethiopia. Ethiop Med J 2006; 44:237-44.
6. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretroviral in resource-poor settings: prevention of HIV infection whilst controlling drug resistance. Curr Drug Targets Infect Disord 2003; 3:345-53.
7. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
8. Nischal KC, Khopkar U, Saple DG. Improving adherence to antiretroviral therapy. Indian J Dermatol Venereol Leprol 2005; 71:316-20.
9. Carter M. Adherence-information series for HIV-positive people. 3rd ed. London: NAM, 2005.
10. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS 2002; 16:1051-8.
11. Adam BD, Maticka TE, Cohen JJ. Adherence practices among people living with HIV. AIDS Care 2003; 15:263-74.
12. Malcolm SE, Ng JJ, Rosen RK, Stone VE. An examination of HIV/AIDS patients who have excellent adherence to HAART. AIDS Care 2003; 15: 251-61.
13. World Health Organization. Adherence to HIV treatment, Geneva; 2003. (Department of HIV/AIDS unpublished internal technical brief).
14. Lameshow S, Lwanga SK. Sample size determination in health studies, a practical manual. Geneva: WHO, 1991.
15. Chesney MA, Ickovics JR, Chamben DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV CLINICAL trial: The AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trial Group (AACTG). AIDS Care 2000; 12:255-66.
16. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40:158-63.
17. Unge C, Södergård B, Marrone G, et al. Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: a prospective cohort study. PLoS One 2010; 5:e13613.
18. Barfod TS, Sørensen HT, Nielsen H, Rodkjaer L, Obel N. "Simply forgot" is most frequently stated reason for missed doses of HAART irrespective of degree of adherence. HIV Med 2006; 7:285-90.
19. Sarna A, Pujari S, Sengar AK, et al. Adherence to antiretroviral therapy & its determinants among HIV patients in India. Indian J Med Res 2008; 127:28-36.
20. Shah B, Walshe L, Saple DG, et al. Adherence to antiretroviral therapy and virologic suppression among hiv-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis 2007; 44:1235-44.
21. Ekstrand ML, Chandy S, Heylen E, Steward W, Singh G. Developing useful highly active antiretroviral therapy adherence measures for India: the Prerana study. J Acquir Immune Defc Syndr 2010; 53:415-6.
22. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-90.
23. Bachani D, Rewari BB. Antiretroviral therapy: practice guidelines and National ART Programme. J Indian Med Assoc 2009; 107:310-4.
24. Sundar Lal, Adarsh Pankaj. Textbook of Community Medicine. 3rd ed. New Delhi: CBS Publishers & Distributors Pvt Ltd, 2011: 17-20.
25. Wanchu A, Kaur R, Bamberry P, Singh S. Adherence to generic reverse transcriptase inhibitor-based antiretroviral medication at a tertiary centre in North India. AIDS Behav 2007; 11:99-102.
26. Lanièce I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003; 17(Suppl 3):S103-8.
27. Orwell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17:1369-75.
28. Ivers L, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-24.
29. Safren S, Kumarasamy N, James R, et al. ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care 2005; 17:853-62.
30. Kumaraswamy N, Safren SA, Raminani SR, et al. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS 2005; 19:526-37.
31. Sarna A, Gupta I, Pujari S, et al. Examining adherence and sexual behaviour among patients on antiretroviral therapy in India. Horizons Final Report Washington, DC: Population Council; 2006.
32. Murri R, Ammassari A, De Luca LA, et al. Self-reported non adherence with antiretroviral drugs predicts persistent condition. HIV Clin Trials 2001; 2:323-329.
33. Frank I. Once-daily HAART: toward a new treatment paradigm. J Acquir Immune Defc Syndr 2002; 31(suppl 1):S10-S5.
34. Fogarty L, Roter D, Larson S, et al. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns 2002; 46:93-108.
35. Cauldbeck MB, O'Connor C, O'Connor MB, et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther 2009; 6:7
36. Paasche-Orlow MK, Cheng DM, Palepu A, et al. Health literacy, antiretroviral adherence, and HIV-RNA suppression: a longitudinal perspective. J Gen Intern Med 2006; 21:835-840.
37. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-90.
38. Igwegbe AO, Ugboaja JO, Nwajiaku LA. Prevalence and determinants of non-adherence to antiretroviral therapy among HIV positive pregnant women in Nnewi, Nigeria. Int J Med Med Sci 2010; 2:238-45.
39. Amberbir A, Woldemichael K, Getachew S, Girma B, Deribe K. Predictors of adherence to antiretroviral therapy among HIV-infected persons: a prospective study in Southwest Ethiopia. BMC Public Health 2008; 8:265.
40. Lee LS, Soon GH, Teo YY. Inter-ethnic differences in efavirenz CNS toxicity - role of cytochrome P450 2B6 polymorphisms. BMC Infect Dis 2012; 12(suppl 1): O17.
41. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 2007; 45:1230-1237.